Targeting the Mitochondrial Chaperone TRAP1 Alleviates Vascular Pathologies in Ischemic Retinopathy (Adv. Sci. 2/2024)

Targeting the Mitochondrial Chaperone TRAP1 Alleviates Vascular Pathologies in Ischemic Retinopathy (Adv. Sci. 2/2024)

Ischemic Retinopathy Ischemic retinopathies exhibit blood‐retinal barrier breakdown and pathological neovascularization, ultimately leading to blindness. In article number 2302776, Dong Ho Park, Byoung Heon Kang, and co‐workers report that genetically or pharmacologically targeting mitochondrial cha...

Full description

Saved in:
Bibliographic Details
Published in:Advanced science Vol. 11; no. 2
Main Authors: Kim, So‐Yeon, Yoon, Nam Gu, Im, Jin Young, Lee, Ji Hye, Kim, Juhee, Jeon, Yujin, Choi, Young Jae, Lee, Jong‐Hwa, Uemura, Akiyoshi, Park, Dong Ho, Kang, Byoung Heon
Format: Journal Article
Language:English
Published: Weinheim John Wiley & Sons, Inc 01-01-2024
John Wiley and Sons Inc
Subjects:
Frontispiece
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Ischemic Retinopathy Ischemic retinopathies exhibit blood‐retinal barrier breakdown and pathological neovascularization, ultimately leading to blindness. In article number 2302776, Dong Ho Park, Byoung Heon Kang, and co‐workers report that genetically or pharmacologically targeting mitochondrial chaperone TRAP1 alleviates ischemic retinopathies. Furthermore, small molecule TRAP1 inhibitors are able to effectively reach the retinas through non‐invasive eye drop applications, reversing retinal pathogenesis. This proposes a novel strategy for developing potent and convenient therapeutics to treat ischemic retinopathies.
ISSN:2198-3844
2198-3844
DOI:10.1002/advs.202470011